Adaptimmune Therapeutics plc (NASDAQ:ADAP) marched up 115.64% compared to a 52-week low price of $3.90. The shares were last seen trading 5.12% higher, taking the closing price at $8.41 on 03/08/2018. At recent session, the prices were hovering between $8.03 and $8.619. This company shares are 54.58% off its target price of $13 and the current market capitalization stands at $789.87M. The recent change has given its price a 4.82% lead over SMA 50 and -13.34% deficit over its 52-week high. The stock witnessed -0.71% declines, 7.82% gains and 24.78% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ADAP’s volatility during a week at 5.03% and during a month it has been found around 6.26%.Adaptimmune Therapeutics plc (ADAP) Top Holders
Institutional investors currently hold around $417 million or 63% in ADAP stock. Look at its top three institutional owners. Matrix Capital Management Company, Lp owns $97.71 million in Adaptimmune Therapeutics plc, which represents roughly 12.37% of the company’s market cap and approximately 23.43% of the institutional ownership. Similar statistics are true for the second largest owner, Nea Management Company, Llc, which owns 12,025,999 shares of the stock are valued at $96.21 million. The third largest holder is Capital World Investors, which currently holds $54.34 million worth of this stock and that ownership represents nearly 6.88% of its market capitalization.
At the end of 12/31/2017 reporting period, 35 institutional holders increased their position in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by some 3,198,080 shares, 28 decreased positions by 1,937,991 and 17 held positions by 46,932,402. That puts total institutional holdings at 52,068,473 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 320,095 shares while 11 institutional investors sold out their entire positions totaling 789,159 shares.Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insider Trades
Multiple company employees have indulged in significant insider trading. Adaptimmune Therapeutics plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Orbimed Advisors Llc has acquired 1,190,476 shares of Adaptimmune Therapeutics plc (ADAP) in trading session dated Mar. 27, 2017. These shares are worth $4,999,999 and were traded at $4.2 each. The SEC filing shows that Thompson Peter A. performed a purchase of 1,190,476 shares. The Director added these shares by way of transaction on Mar. 27, 2017. The company’s shares were assimilated at $4.2 per share worth to an investment of some $4,999,999 on account of Thompson Peter A..
10% Owner, New Enterprise Associates 14,, purchased 12,870,000 common shares of Adaptimmune Therapeutics plc (ADAP) in the open market. In a transaction dated Mar. 27, 2017, the shares were bought at an average price of $0.7, giving away a sum of $9,009,000. After this purchase, 72,139,000 common shares of ADAP are directly owned by the insider, with total stake valued at $606,688,990.
In the transaction dated Mar. 27, 2017, the great number of shares acquired came courtesy the 10% Owner; Barrett M James added a total of 12,870,000 shares at an average price of $0.7, amounting to approximately $9,009,000. The insider now directly owns 72,139,000 shares worth $606,688,990.Adaptimmune Therapeutics plc (ADAP) Analyst Guide
Several analysts have released their opinion on Adaptimmune Therapeutics plc (NASDAQ:ADAP), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.